PartnershipJun 17, 2026, 07:02 AM
Can-Fite to Conduct Partnering Meetings at BIO International Convention
AI Summary
Can-Fite BioPharma Ltd. announced its participation in the BIO International Convention 2026 to conduct partnering meetings with pharmaceutical and biotechnology firms. The company aims to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline, which includes Namodenoson for HCC, pancreatic cancer, and MASH, and Piclidenoson for psoriasis and Lowe Syndrome. Can-Fite seeks to expand on its existing regional licensing agreements, which have already generated approximately $20 million in upfront and milestone payments.
Key Highlights
- Can-Fite BioPharma to participate in BIO International Convention 2026.
- Company will conduct partnering meetings for licensing and commercialization opportunities.
- Namodenoson is in pivotal Phase III for advanced hepatocellular carcinoma (HCC).
- Namodenoson is also in Phase IIb for MASH and completed Phase IIa for pancreatic cancer.
- Piclidenoson is in pivotal Phase III for psoriasis and preparing for Phase II in Lowe Syndrome.
- Proprietary A3AR platform has a favorable safety profile in over 1,600 patients.
- Existing regional licensing agreements have generated approximately $20 million in payments.
Price Impact
More from CANF